Ipsen (IPSEY) posted sales of 822.4 million euros for the first quarter of 2024, up 13.3% at CER, or 10.9% as reported, driven by the 16.2% increase in sales of the growth platforms and the increased contributions from new medicines, while Somatuline sales declined by 1.3%.
David Loew, CEO, Ipsen, said: "The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines. Moreover, the pipeline continues to deliver, illustrated this quarter by the regulatory approval in the U.S. of Onivyde as a first-line treatment for pancreatic cancer."
Ipsen has confirmed its financial guidance for 2024. Total-sales growth are projected greater than 6.0%, at constant currency. Core operating margin is projected around 30% of total sales.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.